Form 4: Director Melissa Starovasnik Sells Twist Bioscience Shares

Director Melissa A. Starovasnik sold 500 shares of Twist Bioscience Corporation common stock on May 26, 2026.

Summary

• Director Melissa A. Starovasnik executed a sale of 500 shares of Twist Bioscience (TWST) common stock.
• The shares were sold at a price of $61.04 per share.
• The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 22, 2025.
• Following this transaction, the director retains beneficial ownership of 24,722 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-arranged 10b5-1 plan, which is a standard administrative procedure for corporate directors.

Positives

• The sale was executed via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term price appreciation of the stock.

Risks

• Market volatility affecting the share price of Twist Bioscience.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector and typically does not signal a change in corporate strategy or fundamental health.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction was pre-planned.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Twist Bioscience, TWST, Insider Trading, Form 4, Biotech, Director Sale